全球多發性硬化症治療藥物市場規模、佔有率、成長分析、按藥物類型、給藥途徑- 2023-2030 年產業預測

Global Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Type(Immunomodulatory, Immunosuppressant), By Route of Administration(Oral and Parenteral) - Industry Forecast 2023-2030

出版日期: 2024年02月11日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球多發性硬化症藥物市場規模為246.4億美元，預測期間（2024-2031年）複合年成長率為3.10%，從2023年的254億美元增至2031年的32.4億美元。成長至3000萬美元。

由於多發性硬化症（MS）增加等因素，該市場預計未來將快速成長。根據2020年12月出版的《多發性硬化症圖譜第三版洞察》，全球約有280萬人（每10萬人中有35.9人）受到多發性硬化症的影響。全球多發性硬化症的患病率正在增加，但盛行率估計值仍有差距在所有 75 個報告國家中，總總合為每年每10 萬人中2.1 例，平均診斷年齡為32 歲。女性被診斷患有MS 的可能性也是男性的兩倍。

使用自上而下和自下而上的方法來估計和檢驗全球多發性硬化症藥物市場的規模，並估計其他各個相關子市場的規模。用於估計市場規模的調查方法包括以下細節：透過二次研究確定市場的主要企業，並透過初步和二次研究確定每個地區的市場佔有率。整個過程包括研究主要企業的年度報告和財務報告，以及廣泛的採訪，以獲取首席執行官、副總裁、董事和行銷負責人等行業領導者的關鍵見解。馬蘇。所有股份比率和細分均使用二手資訊確定並使用主要資訊檢驗。本研究涵蓋的所有可能影響市場的參數都經過詳細考慮，並透過初步研究檢驗並進行分析，以獲得最終的定量和定性資料。

全球多發性硬化症藥物細分市場分析

多發性硬化症藥物的全球市場根據藥物類型、給藥途徑和地區進行細分。依藥物類型分類，市場分為免疫調節劑、免疫抑制劑、干擾素和皮質類固醇。依給藥途徑，市場分為口服藥物和腸胃外藥物。依地區分類，分為北美、歐洲、亞太地區、中東/非洲、拉丁美洲。

推動多發性硬化症藥物全球市場的因素

目前用於治療多發性硬化症的藥物經常接受進一步的測試，以了解更多用途或擴大適應症。例如，某些最初批准用於復發緩解型多發性硬化症的藥物後來被批准用於次發性進行性和臨床孤立症候群。這一擴大的適應症擴大了可能受益於這些藥物的患者範圍，從而增加了銷售並擴大了市場。

在許多國家，政府和保險公司對用於治療多發性硬化症（MS）的藥物製定了優惠的報銷政策。這些政策旨在透過減輕患者的經濟負擔來改善患者獲得藥物的機會。提供報銷支持將使更多患者能夠負擔昂貴的多發性硬化症藥物，從而推動市場成長。

全球多發性硬化症藥物市場的限制因素

多發性硬化症藥物，尤其是新的疾病修正治療，通常成本高。這些成本給患者、醫療保健系統和付款人帶來了巨大的經濟挑戰。對昂貴的多發性硬化症藥物的價格和可用性的限制可能會阻礙其普及並抑制市場擴張，特別是在醫療保健預算有限和保險覆蓋範圍不足的地區。

全球多發性硬化症治療藥物市場趨勢

疾病修正治療(DMT) 的進步對於多發性硬化症的治療至關重要。這是因為DMT在降低復發率、減緩疾病進展和保護神經功能方面發揮作用。市面上不斷出現具有更高功效和安全性的新型增強型 DMT，包括單株抗體和口服療法。 DMT 增強仍然是市場驅動力，為患者提供廣泛的疾病管理選擇。

執行摘要
調查方法
母市場分析
主要市場考察
- 技術分析
- 價格分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 智慧財產權分析
- 貿易分析
- Start-Ups分析
- 原料分析
- 創新矩陣
- 研發線產品分析
- 總體經濟指標
- 主要投資分析
- 關鍵成功因素
- 競爭程度
市場動態及展望
- 市場動態
  - 促進因素
  - 機會
  - 抑制因素
  - 任務
- 監管形勢
- 波特的分析
- 對未來中斷的特殊考慮
多發性硬化症藥物的全球市場：依藥物類型
- 市場概況
- 免疫調節
- 免疫抑制劑
- 干擾素
- 皮質類固醇
多發性硬化症藥物的全球市場：按給藥途徑
- 市場概況
- 口服和腸胃外
多發性硬化症藥物的全球市場規模：按地區分類
- 市場概況
- 北美洲
  - 美國
  - 加拿大
- 歐洲
  - 德國
  - 西班牙
  - 法國
  - 英國
  - 其他歐洲國家地區
- 亞太地區
  - 中國
  - 印度
  - 日本
  - 韓國
  - 其他亞太地區
- 拉丁美洲
  - 巴西
  - 其他拉丁美洲地區
- 中東和非洲 (MEA)
  - 海灣合作理事會國家
  - 南非
  - 其他中東/非洲地區
競爭形勢
- 前5名企業對比
- 主要企業市場定位（2021年）
- 主要市場參與者所採取的策略
- 關鍵成功策略
- 近期市集活動
- 主要企業市場佔有率（2021年）
主要企業簡介
- Biogen Inc.（United States）
- Roche Holdings AG（Switzerland）
- Novartis AG（Switzerland）
- Sanofi SA（France）
- Merck & Co., Inc.（United States）
- Teva Pharmaceutical Industries Ltd.（Israel）
- Bayer AG（Germany）
- Pfizer Inc.（United States）
- GlaxoSmithKline plc（United Kingdom）
- AbbVie Inc.（United States）
- Johnson & Johnson Services, Inc.（United States）
- Celgene Corporation（United States）
- Bristol-Myers Squibb Company（United States）
- Mitsubishi Tanabe Pharma Corporation（Japan）
- Biogen Idec International GmbH（Switzerland）
- Genzyme Corporation（United States）
- F. Hoffmann-La Roche Ltd（Switzerland）
- Merck KGaA（Germany）
- Mylan NV（United States）
- Eisai Co., Ltd.（Japan）
- Takeda Pharmaceutical Company Limited（Japan）
- Ipsen（France）

簡介目錄

Product Code: SQMIG35I2199

Global Multiple Sclerosis Drugs Market size was valued at USD 24.64 Billion in 2022 and is poised to grow from USD 25.40 Billion in 2023 to USD 32.43 Billion by 2031, at a CAGR of 3.10% during the forecast period (2024-2031).

Due to factors such as the rising occurrence of multiple sclerosis (MS), the market in focus is expected to witness rapid growth in the future. According to a study published in December 2020 titled "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition," it is estimated that approximately 2.8 million individuals (equating to 35.9 per 100,000 people) worldwide are believed to be affected by MS. The prevalence of MS has shown a global increase, although there are still gaps in the estimates of prevalence. Across all 75 reporting nations, the combined incidence rate stands at 2.1 per 100,000 people annually, with an average age of diagnosis being 32. Additionally, females are twice as likely as males to be diagnosed with MS.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Drugs Market Segmental Analysis

Global Multiple Sclerosis Drugs Market is segmented on the basis of Drug Type, Route of Administration and region. By Drug Type, the market is segmented into Immunomodulatory, Immunosuppressant, Interferons, Corticosteroids. By Route of Administration, market is segmented into Oral and Parenteral. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Multiple Sclerosis Drugs Market

Drugs currently utilized in multiple sclerosis treatment are frequently subjected to further testing for additional uses and expanded indications. For instance, certain medications initially sanctioned for relapsing-remitting MS have subsequently obtained approvals for secondary progressive MS or clinically isolated syndrome. These expanded indications broaden the range of patients who can potentially benefit from these drugs, thereby resulting in heightened sales and market expansion.

In numerous countries, governments and insurance firms have instituted favourable reimbursement policies for drugs used in treating multiple sclerosis (MS). These policies are designed to enhance patient access to medications by alleviating financial burdens. By providing reimbursement support, more patients can afford costly MS drugs, thereby stimulating market growth.

Restraints in the Global Multiple Sclerosis Drugs Market

MS medications, particularly the newer disease-modifying therapies, are frequently linked with considerable expenses. These costs can impose significant financial challenges on patients, healthcare systems, and payers alike. The restricted affordability and access to expensive MS drugs may hinder their uptake and constrain market expansion, particularly in areas with constrained healthcare budgets or insufficient insurance coverage.

Market Trends of the Global Multiple Sclerosis Drugs Market

The advancement of disease-modifying therapies (DMTs) is pivotal in the management of MS, as they serve to decrease relapse rates, postpone disease advancement, and safeguard neurological function. The market has seen the emergence of novel and enhanced DMTs, including monoclonal antibodies and oral treatments, which offer improved efficacy and safety attributes. The emphasis on enhancing DMTs remains a driving force in the market, offering patients a broader array of choices for managing the disease.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
- Regulatory Landscape
- Porters Analysis
  - Competitive rivalry
  - Threat of Substitute Products
  - Bargaining Power of Buyers
  - Threat of New Entrants
  - Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
  - Political Impact
  - Economic Impact
  - Social Impact
  - Technical Impact
  - Environmental Impact
  - Legal Impact
Global Multiple Sclerosis Drugs Market by Drug Type
- Market Overview
- Immunomodulatory
- Immunosuppressant
- Interferons
- Corticosteroids
Global Multiple Sclerosis Drugs Market by Route of Administration
- Market Overview
- Oral and Parenteral
Global Multiple Sclerosis Drugs Market Size by Region
- Market Overview
- North America
  - USA
  - Canada
- Europe
  - Germany
  - Spain
  - France
  - UK
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - South Korea
  - Rest of Asia-Pacific
- Latin America
  - Brazil
  - Rest of Latin America
- Middle East & Africa (MEA)
  - GCC Countries
  - South Africa
  - Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
  - By Development
  - By Company
  - By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Biogen Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Roche Holdings AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Novartis AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Sanofi S.A. (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck & Co., Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bayer AG (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Pfizer Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- GlaxoSmithKline plc (United Kingdom)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- AbbVie Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Johnson & Johnson Services, Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Celgene Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bristol-Myers Squibb Company (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mitsubishi Tanabe Pharma Corporation (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Biogen Idec International GmbH (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Genzyme Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck KGaA (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mylan N.V. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Eisai Co., Ltd. (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Ipsen (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments